Company Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Country | United States |
| IPO Date | May 7, 2015 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 197 |
| CEO | Michael Thomas Heffernan B.S. Pharm, R.Ph. |
Contact Details
Address: 100 Technology Center Drive Stoughton, Massachusetts 02072 United States | |
| Phone | 781-713-3699 |
| Website | collegiumpharma.com |
Stock Details
| Ticker Symbol | COLL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001267565 |
| CUSIP Number | 19459J104 |
| ISIN Number | US19459J1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph J. Ciaffoni | President, Chief Executive Officer and Director |
| Michael Thomas Heffernan B.S. Pharm, R.Ph. | Co-Founder and Independent Chairman |
| Colleen Tupper | Executive Vice President and Chief Financial Officer |
| Shirley R. Kuhlmann | Executive Vice President, General Counsel, Chief Administrative Officer and Secretary |
| Scott Dreyer | Executive Vice President and Chief Commercial Officer |
| Dr. Thomas B. Smith FAAFP, M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Christopher Shayne James M.D. | Vice President of Investor Relations |
| Bart J. Dunn | Executive Vice President of Strategy and Corporate Development |
| Scott Sudduth | Head of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2024 | 8-K | Current Report |
| Jun 5, 2024 | 144 | Filing |
| Jun 4, 2024 | 144 | Filing |
| Jun 3, 2024 | 144 | Filing |
| Jun 3, 2024 | 144 | Filing |
| May 30, 2024 | 144 | Filing |
| May 29, 2024 | 144/A | Filing |
| May 29, 2024 | 144 | Filing |
| May 28, 2024 | 144 | Filing |
| May 28, 2024 | 144 | Filing |